APLS Apellis: Rasio nilai perusahaan marang pendapatan

Apellis Pharmaceuticals, Inc. (APLS) - logo korporat

Apellis Pharmaceuticals (APLS) is demonstrating confident revenue growth driven by the expansion of its primary drug for geographic atrophy. The company's high scientific and technical potential is based on protein bioengineering and targeted retinal therapy. Stable demand for unique vision-preserving treatments guarantees long-term sales. After evaluating the EV/Sales ratio on GURU.Markets, we find that the 4814.79 metric determines the status of the business value parameter relative to revenue.

Apellis Pharmaceuticals (APLS) - Multiplikator EV/Sales saka 23.11.2025 nganti 30.05.2026

Rincian metrik keuangan lan pasar Apellis Pharmaceuticals Inc (APLS)

- rega lan prakiraan konsensus rega:
- data kapitalisasi saham perusahaan:
Analisis wiwitan perusahaan:Apellis Pharmaceuticals
Produk asli Apellis Pharmaceuticals, Inc.

This indicator determines the enterprise value of the business, accounting for net debt, relative to annual sales volume. By analyzing the company's valuation via EV/Sales, an investor sees the real price per unit of revenue without distortions from the debt load. For Apellis Pharmaceuticals (APLS), this metric is critical: it reflects the commercialization efficiency of its blockbuster during a period of expansion through international licensing without the costs associated with mergers.